Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Allogenic Mesenchymal Stem cell Therapy for CADASIL patient: first clinical Case Report

*Corresponding Author:

Copyright: © 2021  . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 
To read the full article Peer-reviewed Article PDF image

Abstract

CADASIL, Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy, is an
inherited small vessels disease that characterized by central nervous system dysfunctions caused by mutations
in the Notch-3 gene. Clinical manifestations accrue due to brain’s vasculopathy, neurodegeneration, and immune
system reaction. We describe here an effective method for treatment of CADASIL by using mesenchymal stem
cell therapy. A CADASIL case, 36 years old man, neuroimaging and genetic analysis for Notch-3 confirmed the
diagnosis, is reported. In the present case, two stem cell injections have been performed at intervals of three weeks.

Top